Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Inovio Pharmaceuticals, Inc. before investing.

In this article, we go over a few key elements for understanding Inovio Pharmaceuticals, Inc.’s stock price such as:

• Inovio Pharmaceuticals, Inc.’s current stock price and volume
• Why Inovio Pharmaceuticals, Inc.’s stock price changed recently
• Upgrades and downgrades for INO from analysts
• INO’s stock price momentum as measured by its relative strength

About Inovio Pharmaceuticals, Inc. (INO)

Before we jump into Inovio Pharmaceuticals, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company’s lead product candidate is INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade squamous intraepithelial lesions; INO-3112 for the treatment of HPV-related Oropharyngeal squamous cell carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 2/3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. The company’s partners and collaborators ApolloBio Corporation, AstraZeneca, Coherus Biosciences, Defense Advanced Research Projects Agency, HIV Vaccines Trial Network, Kaneka Eurogentec, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the University of Pennsylvania, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Want to learn more about Inovio Pharmaceuticals, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Inovio Pharmaceuticals, Inc..

Inovio Pharmaceuticals, Inc.’s Stock Price as of Market Close

As of March 31, 2026, 4:00 PM, CST, Inovio Pharmaceuticals, Inc.’s stock price was $1.740.

Inovio Pharmaceuticals, Inc. is up 4.19% from its previous closing price of $1.670.

During the last market session, Inovio Pharmaceuticals, Inc.’s stock traded between $1.670 and $1.790. Currently, there are approximately 62.03 million shares outstanding for Inovio Pharmaceuticals, Inc..

Inovio Pharmaceuticals, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Inovio Pharmaceuticals, Inc. Stock Price History

Inovio Pharmaceuticals, Inc.’s (INO) price is currently down 3.87% so far this month.

During the month of March, Inovio Pharmaceuticals, Inc.’s stock price has reached a high of $1.800 and a low of $1.500.

Over the last year, Inovio Pharmaceuticals, Inc. has hit prices as high as $2.979 and as low as $1.300. Year to date, Inovio Pharmaceuticals, Inc.’s stock is down 0%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Inovio Pharmaceuticals, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of March 31, 2026, there were 0 analysts who downgraded Inovio Pharmaceuticals, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Inovio Pharmaceuticals, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Inovio Pharmaceuticals, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Inovio Pharmaceuticals, Inc. (INO) by visiting AAII Stock Evaluator.

Relative Price Strength of Inovio Pharmaceuticals, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of March 31, 2026, Inovio Pharmaceuticals, Inc. has a weighted four-quarter relative price strength of 0.30%, which translates to a Momentum Score of 49 and is considered to be Average.

Want to learn more about how Inovio Pharmaceuticals, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Inovio Pharmaceuticals, Inc. Stock Price: Bottom Line

As of March 31, 2026, Inovio Pharmaceuticals, Inc.’s stock price is $1.740, which is up 4.19% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Inovio Pharmaceuticals, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.